Giulia Ciotti

Dr. Giulia Ciotti

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Vittoria RaimondiVittoria Raimondi
Vittoria Raimondi
GCGiulia Ciotti
Giulia Ciotti
MGMichele Gottardi
Michele Gottardi
Francesco CiccareseFrancesco Ciccarese
Francesco Ciccarese
The oncometabolite 2-hydroxyglutarate (2-HG) plays a key role in differentiation blockade and metabolic reprogramming of cancer cells. Approximatively 20–30% of acute myeloid leukemia (AML) cases carry mutations in the isocitrate dehydrogenase (IDH) enzymes, leading to a reduction in the Krebs cycle intermediate α-ketoglutarate (α-KG) to 2-HG. Relapse and chemoresistance of AML blasts following initial good response to standard therapy account for the very poor outcome of this pathology, which represents a great challenge for hematologists. The decrease of 2-HG levels through pharmacological inhibition of mutated IDH enzymes induces the differentiation of AML blasts and sensitizes leukemic cells to several anticancer drugs. In this review, we provide an overview of the main genetic mutations in AML, with a focus on IDH mutants and the role of 2-HG in AML pathogenesis. Moreover, we discuss the impact of high levels of 2-HG on the response of AML cells to antileukemic therapies and recent evidence for highly efficient combinations of mutant IDH inhibitors with other drugs for the management of relapsed/refractory (R/R) AML.

26 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAlessandra Sperotto
Alessandra Sperotto
MBMaria Teresa Bochicchio
Maria Teresa Bochicchio
Giorgia SimonettiGiorgia Simonetti
Giorgia Simonetti
Francesco BuccisanoFrancesco Buccisano
Francesco Buccisano
JPJacopo Peccatori
Jacopo Peccatori
MGMichele Gottardi
Michele Gottardi
It has now been ascertained that acute myeloid leukemias—as in most type of cancers—are mixtures of various subclones, evolving by acquiring additional somatic mutations over the course of the disease. The complexity of leukemia clone architecture and the phenotypic and/or genotypic drifts that can occur during treatment explain why more than 50% of patients—in hematological remission—could relapse. Moreover, the complexity and heterogeneity of clone architecture represent a hindrance for monitoring measurable residual disease, as not all minimal residual disease monitoring methods are able to detect genetic mutations arising during treatment. Unlike with chemotherapy, which imparts a relatively short duration of selective pressure on acute myeloid leukemia clonal architecture, the immunological effect related to allogeneic hematopoietic stem cell transplant is prolonged over time and must be overcome for relapse to occur. This means that not all molecular abnormalities detected after transplant always imply inevitable relapse. Therefore, transplant represents a critical setting where a measurable residual disease-based strategy, performed during post-transplant follow-up by highly sensitive methods such as next-generation sequencing, could optimize and improve treatment outcome. The purpose of our review is to provide an overview of the role of next-generation sequencing in monitoring both measurable residual disease and clonal evolution in acute myeloid leukemia patients during the entire course of the disease, with special focus on the transplant phase.

1 February 2023 in Expert Opinion on Biological Therapy
Verified
Journal Article
Open access
GCGiulia Ciotti
Giulia Ciotti
GMGiovanni Marconi
Giovanni Marconi
ASAlessandra Sperotto
Alessandra Sperotto
MGMaria B Giannini
Maria B Giannini
MGMichele Gottardi
Michele Gottardi
GMGiovanni Martinelli
Giovanni Martinelli
The introduction of target molecules and immunological therapies are changing the treatment landscape of acute myeloid leukemia (AML).We recapitulate the biological therapies that can be employed i...

31 March 2023 in Cancer Medicine
Verified
Journal Article
Open access
ACAnna Candoni
Anna Candoni
RNRoberta Di Nicola
Roberta Di Nicola
CSChiara Sartor
Chiara Sartor
SPSarah Parisi
Sarah Parisi
MAMariachiara Abbenante
Mariachiara Abbenante
ACAntonio Curti
Antonio Curti
Background: In older patients with acute myeloid leukemia (AML), the definition of fitness, prognosis, and risk of death represents an open question.Methods: In the present study, we tested the impact on survival of disease‐ and patient‐related parameters in a large cohort of elderly AML patients homogeneously assigned to treatment with hypomethylating agents (HMAs).Results: In 131 patients with a median age of 76 years, we confirmed that early response (<0.001) and biology‐based risk classification (p = 0.003) can select patients with better‐predicted survival. However, a full disease‐oriented model had limitations in stratifying our patients, prompting us to investigate the impact of baseline comorbidities on overall survival basing on a comorbidity score. The albumin level (p = 0.001) and the presence of lung disease (p = 0.013) had a single‐variable impact on prognosis. The baseline comorbidity burden was a powerful predictor of patients' frailty, correlating with increased incidence of adverse events, especially infections, and predicted overall survival (p < 0.001).Conclusion: The comorbidity burden may contribute to impact prognosis in addition to disease biology. While the therapeutic armamentarium of elderly AML is improving, a comprehensive approach that combines AML biology with tailored interventions to patients' frailty is likely to fully exploit the anti‐leukemia potential of novel drugs.

9 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMichele Gottardi
Michele Gottardi
FMFederico De Marchi
Federico De Marchi
GCGiulia Ciotti
Giulia Ciotti
MBMarco Basso
Marco Basso
Vittoria RaimondiVittoria Raimondi
Vittoria Raimondi
ASAlessandra Sperotto
Alessandra Sperotto
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem-cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.

27 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MGMichele Gottardi
Michele Gottardi
FMFederico De Marchi
Federico De Marchi
GCGiulia Ciotti
Giulia Ciotti
MBMarco Basso
Marco Basso
Vittoria RaimondiVittoria Raimondi
Vittoria Raimondi
ASAlessandra Sperotto
Alessandra Sperotto
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.